These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38815129)

  • 1. Nanoparticle-Mediated Immunotherapy in Triple-Negative Breast Cancer.
    Wang R; Huang X; Chen X; Zhang Y
    ACS Biomater Sci Eng; 2024 Jun; 10(6):3568-3598. PubMed ID: 38815129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapeutic interventions of Triple Negative Breast Cancer.
    Li Z; Qiu Y; Lu W; Jiang Y; Wang J
    J Transl Med; 2018 May; 16(1):147. PubMed ID: 29848327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoparticles for Chemoimmunotherapy Against Triple-Negative Breast Cancer.
    Liu S; Li J; Gu L; Wu K; Xing H
    Int J Nanomedicine; 2022; 17():5209-5227. PubMed ID: 36388877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in triple-negative breast cancer.
    Katz H; Alsharedi M
    Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for Triple-Negative Breast Cancer: Latest Research and Clinical Prospects.
    Ahmed RF; Jameel F; Irfan M
    Crit Rev Immunol; 2019; 39(3):211-221. PubMed ID: 32421965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterologous prime-boost cellular vaccination induces potent antitumor immunity against triple negative breast cancer.
    Niavarani SR; St-Cyr G; Daniel L; Lawson C; Giguère H; Alkayyal AA; Tai LH
    Front Immunol; 2023; 14():1098344. PubMed ID: 36860852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials.
    Hall PE; Schmid P
    Expert Opin Emerg Drugs; 2021 Jun; 26(2):131-147. PubMed ID: 33870839
    [No Abstract]   [Full Text] [Related]  

  • 9. Recent advances in nanotheranostics for triple negative breast cancer treatment.
    Thakur V; Kutty RV
    J Exp Clin Cancer Res; 2019 Oct; 38(1):430. PubMed ID: 31661003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Photothermal Ferrotherapy - Induced Immunogenic Cell Death via Iron-Based Ternary Chalcogenide Nanoparticles Against Triple-Negative Breast Cancer.
    Wu Q; Li Z; Zhou X; Wei Z; Ramadan S; Xu Y; Xu L; Li D
    Small; 2024 May; 20(20):e2306766. PubMed ID: 38095479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC).
    Michaels E; Chen N; Nanda R
    Clin Breast Cancer; 2024 Jun; 24(4):263-270. PubMed ID: 38582617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single peptides and combination modalities for triple negative breast cancer.
    Razazan A; Behravan J
    J Cell Physiol; 2020 May; 235(5):4089-4108. PubMed ID: 31642059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1/PD-L1 immune checkpoint blocking.
    He R; Yuan X; Chen Z; Zheng Y
    Int Immunopharmacol; 2022 Dec; 113(Pt B):109444. PubMed ID: 36402069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Blockade in Patients with Triple-Negative Breast Cancer.
    Michel LL; von Au A; Mavratzas A; Smetanay K; Schütz F; Schneeweiss A
    Target Oncol; 2020 Aug; 15(4):415-428. PubMed ID: 32514907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evolving role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer.
    Steiner M; Tan AR
    Clin Adv Hematol Oncol; 2021 May; 19(5):305-315. PubMed ID: 33989278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Checkpoint blockade in the treatment of breast cancer: current status and future directions.
    Wein L; Luen SJ; Savas P; Salgado R; Loi S
    Br J Cancer; 2018 Jul; 119(1):4-11. PubMed ID: 29808015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress and challenges of immunotherapy in triple-negative breast cancer.
    Zhu Y; Zhu X; Tang C; Guan X; Zhang W
    Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188593. PubMed ID: 34280474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in Combination with Chemotherapy for Triple-negative Breast Cancer.
    Elizabeth MS; Cristina SBJ; Christian CG
    Mini Rev Med Chem; 2024; 24(4):431-439. PubMed ID: 37198990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous patient-derived exhausted nano T-cells exploit tumor immune evasion to engage an effective cancer therapy.
    Blaya-Cánovas JL; Griñán-Lisón C; Blancas I; Marchal JA; Ramírez-Tortosa C; López-Tejada A; Benabdellah K; Cortijo-Gutiérrez M; Cano-Cortés MV; Graván P; Navarro-Marchal SA; Gómez-Morales J; Delgado-Almenta V; Calahorra J; Agudo-Lera M; Sagarzazu A; Rodríguez-González CJ; Gallart-Aragón T; Eich C; Sánchez-Martín RM; Granados-Principal S
    Mol Cancer; 2024 May; 23(1):83. PubMed ID: 38730475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineering nanoparticles boost TNBC therapy by CD24 blockade and mitochondrial dynamics regulation.
    Zhao M; Li J; Chen F; Han Y; Chen D; Hu H
    J Control Release; 2023 Mar; 355():211-227. PubMed ID: 36736908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.